The agreement to expand access to Alvotech's Humira biosimilar, Adalimumab-ryvk, in the US is a significant development for the company. This move not only enhances the company's product portfolio but also its market penetration and potential revenue streams in the lucrative US market. Given the size of the market for biosimilars and the demand for cost-effective alternatives to branded biologics, this agreement is expected to be viewed positively by investors, leading to a short-term increase in Alvotech's stock price.